Shares of Indian pharma companies with significant exposure to the US, including Gland Pharma, Aurobindo Pharma, Dr. Reddy's Laboratories, and Sun Pharma, surged by up to 14% on Thursday, April 3, after U.S. President Donald Trump refrained from imposing new reciprocal tariffs on the sector.